NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen
08 September 2023 - 6:05AM
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage
biopharmaceutical company committed to discovering and developing
novel, first-in-class immunomedicines to treat cancer and other
immune-related diseases, today announced the publication of a
review article in the online journal Frontiers in Immunology,
highlighting the need for targeting tumor collagen in the
extracellular matrix (ECM) in the tumor microenvironment to enhance
anti-tumor immunity.
“Emerging data on the effects of dysregulated collagen in the
ECM show that it modulates accessibility and activity of immune
cells within the TME, leading to suboptimal oncology treatment
outcomes,” said Solomon Langermann, Ph.D., NextCure’s chief
scientific officer. “A key aspect of what we highlighted in this
review is that an expanded understanding and cross-fertilization
within the fields of tumor matrix biology, cancer biology, and
immunology will contribute to improving the efficacy of cancer
therapeutics. Importantly, it will enable the development of new
classes of therapeutics to address the unmet needs of cancer
patients who do not benefit from current therapies. This is a key
focus of our ongoing NC410 clinical trial.”
The publication, titled “Regulation of Tumor Immunity and
Immunotherapy by the Tumor Collagen Extracellular Matrix,” details
how ECM components, specifically collagen, have an active role in
immune regulation when dysregulated. Collagen acts as a ligand and
interacts with receptors on immune cells to inhibit immune cell
subpopulations in the TME. Such interactions disable anti-tumor
immune responses and promote tumor growth. In addition, the review
highlights how the structural components of the dysregulated ECM
create a physical barrier to immune infiltration, further impeding
the overall immune response and contributing to tumor progression.
The ECM is a major factor in facilitating not only tumor
progression, but resistance to various therapeutic treatments,
including immunotherapy.
The review was published in collaboration with Nordic Bioscience
A/S, a world-leading ECM biomarker specialist.
About NC410NC410 is a first-in-class
immunomedicine designed to block immune suppression mediated by
LAIR-1, an immunomodulatory receptor expressed on T cells and
myeloid cells, including dendritic cells, a type of antigen
presenting cell. In preclinical research, it has been shown that
LAIR-1 inhibits T cell function and myeloid activity. In
preclinical studies, NC410 blocks the negative effects of LAIR-1
and promotes T cell function and myeloid cell activity. NextCure
believes NC410 has the potential to treat multiple cancer
types.
About NextCure, Inc.NextCure is a
clinical-stage biopharmaceutical company committed to discovering
and developing novel, first-in-class immunomedicines to treat
cancer and other immune-related diseases. Through our proprietary
FIND-IO™ platform, we study various immune cells to discover and
understand targets and structural components of immune cells and
their functional impact in disease in order to develop
immunomedicines. Our focus is to bring hope and new treatments to
patients who do not respond to current cancer therapies, patients
whose cancer progresses despite treatment and patients with cancer
types not adequately addressed by available
therapies. http://www.nextcure.com
Cautionary Statement Regarding Forward-Looking
StatementsStatements made in this press release that are
not historical facts are forward-looking statements. Words such as
“expects,” “believes,” “intends,” “hope,” “forward” and similar
expressions are intended to identify forward-looking statements.
Examples of forward-looking statements in this press release
include, among others, statements about NextCure’s plans,
objectives, and intentions with respect to the discovery of
immunomedicine targets and the discovery and development of
immunomedicines. Forward-looking statements involve substantial
risks and uncertainties that could cause actual results to differ
materially from those projected in any forward-looking statement.
Such risks and uncertainties include, among others: our limited
operating history and no products approved for commercial sale; our
history of significant losses; our need to obtain additional
financing; risks related to clinical development, including that
early clinical data may not be confirmed by later clinical results;
risks that pre-clinical research may not be confirmed in clinical
trials; risks related to marketing approval and commercialization;
and the unproven approach to the discovery and development of
product candidates based on our FIND-IO platform. More detailed
information on these and additional factors that could affect
NextCure’s actual results are described in NextCure’s filings with
the Securities and Exchange Commission (the “SEC”),
including NextCure’s most recent Form 10-K and subsequent Form
10-Q. You should not place undue reliance on any
forward-looking statements. NextCure assumes no
obligation to update any forward-looking statements, even if
expectations change.
Investor InquiriesTimothy Mayer, Ph.D.NextCure,
Inc.Chief Operating Officer(240) 762-6486IR@nextcure.com
NextCure (NASDAQ:NXTC)
Historical Stock Chart
From May 2024 to Jun 2024
NextCure (NASDAQ:NXTC)
Historical Stock Chart
From Jun 2023 to Jun 2024